the aid library

LIST OPTIONS

Filter

1620

Sort by:

Direction:

Download (239)

View PDF (278)

Technical handbook for dengue surveillance, dengue outbreak prediction/detection and outbreak response (“model contingency plan”)

World Health Organization WHO; TDR Program (2017) C_WHO

The aim of this “model contingency plan” is to assist programme managers and planners in devel-oping a national, context-specific, dengue outbreak response plan in order to: (a) detect a dengue outbreak at an early stage through clearly defined and validated alarm signals; (b) precisely define w... more

Download (267)

View PDF (1448)

IDF Diabetes Atlas 2021

International Diabetes Federation IDF (2022) C1

10th edition The IDF Diabetes Atlas 10th edition provides detailed information on the estimated and projected prevalence of diabetes, globally, by region, country and territory, for 2021, 2030 and 2045. It draws attention to the growing impact of diabetes across the world and highlights proven and ... more

Download (85)

View PDF (289)

Acute Chagas Disease: New Global Challenges for an Old Neglected Disease

Andrade, D.; Gollob, K.; Dutra, W. PLoS Neglected Tropical diseases (2015) CC

Abstract: Chagas disease is caused by infection with the protozoan Trypanosoma cruzi, and although over 100 years have passed since the discovery of Chagas disease, it still presents an increasing problem for global public health. A plethora of information concerning the chronic phase of human Chaga... more

Download (143)

View PDF (218)

Chagas Disease: Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV

Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV Clinical Info HIV (2018) CC

Epidemiology Chagas disease (American trypanosomiasis) is caused by the protozoan parasite Trypanosoma cruzi, and transmitted to humans by infected triatomine bugs, and less commonly by transfusion, organ transplant, from mother to infant, and in rare instances, by ingestion of contaminated food or... more

Download (76)

View PDF (406)

Guidelines for the Prevention and Treatment of Opportunistic Infections

Clinical Info HIV gov. (2018) CC

Chagas disease (American trypanosomiasis) is caused by the protozoan parasite Trypanosoma cruzi, and transmitted to humans by infected triatomine bugs, and less commonly by transfusion, organ transplant, from mother to infant, and in rare instances, by ingestion of contaminated food or drink.1-4 The... more

Download (92)

View PDF (477)

Melarsoprol Resistance in African Trypanosomiasis

Fairlamb, A.H.; Horn, D. Elsevier Ltd. (2018) CC

Arsenical monotherapies were previously very successful for treating human African trypanosomiasis (HAT). Melarsoprol resistance emerged as early as the 1970s and was widespread by the late 1990s. Melarsoprol resistance represents the only example of widespread drug resistance in HAT patients wher... more

Download (101)

View PDF (460)

Standard Treatment Guidline: Management of Snake Bite

Ministry of Health and Family Welfare - Government of India (2016) CC

Snakebite is an acute life threatening time limiting medical emergency. It is a preventable public health hazard often faced by rural population in tropical and subtropical countries with heavy rainfall and humid climate.

Download (129)

View PDF (158)

Epidemiology of human African trypanosomiasis

Franco J, Simarro P, Diarra A, Jannin J (2014) CC

The epidemiology of the disease is mediated by the interaction of the parasite (trypanosome) with the vectors (tsetse flies), as well as with the human and animal hosts within a particular environment. Related to these interactions, the disease is confined in spatially limited areas called “foci�... more

Download (101)

View PDF (121)

Clinical utlity of peptide microarrys in the serodiagnosis of neglected tropical diseases in sub-Saharan Africa: protocol for a diagnostic test accuracy sytematic review

Vengesai A., Naicker T., Kasambala M., et al. BMJ Open (2021) C2

Neglected tropical diseases tend to cluster in the same poor populations, and to make progress with their control, they will have to be dealt with in an integrated manner. Peptide microarrays may be a solution to tese problems, where diagnosis for co-infection can be detected simultaneously using th... more

Download (145)

View PDF (181)

Praziquantel for the treatment of schistosomiasis during human pregnancy

Friedman, J.F. et al. (2018) CC

In 2014, an estimated 40 million women of reproductive age were infected with Schistosoma haematobium, S. japonicum and/or S. mansoni. In both 2003 and 2006, the World Health Organization (WHO) recommended that all schistosome-infected pregnant and breastfeeding women be offered treatment, with praz... more

Download (89)

View PDF (589)

National Guidelines on Nutrition Care, Support, and Treatment (NCST) for Adolescent and Adults. Second edition 2017

Ministry of Health Malawi (2017) CC

National Guidelines on Nutrition, Care, Support, and Treatment (NCST) for Adolescents and Adults These guidelines are intended to: • Establish a consistent set of nutrition interventions and recommendations aimed at managing and preventing undernutrition and overnutrition in adolescents and ad... more

Download (83)

View PDF (319)

A framework for the quantification and economic valuation of health outcomes originating from health and non-health climate change mitigation and adaptation action

World Health Organization WHO (2023) C_WHO

This report presents a framework to link science, policy and practice for a comprehensive assessment of climate mitigation and adaptation investments and their impact on human health.The framework proposes to use weather and climate data to forecast health impacts over time, as well as biophysical a... more

Download (165)

View PDF (302)

Burden of disease attributable to unsafe drinking-water, sanitation and hygiene: 2019 update

World Health Organisation (WHO) (2023) C_WHO

The report summarizes the estimates of the burden of disease attributable to unsafe drinking water, sanitation, and hygiene for the year 2019 for four health outcomes - diarrhoea, acute respiratory infections, soil-transmitted helminthiases, and undernutrition - which are included in the reporting o... more

Download (95)

View PDF (343)

Assessing development assistance for child survival between 2000 and 2014: A multisectoral perspective

Lu, C.; A. Chu, Z. Li et al. PLOS One (2017) CC

The majority of Countdown countries did not reach the fourth Millennium Development Goal (MDG 4) on reducing child mortality, despite the fact that donor funding to the health sector has drastically increased. When tracking aid invested in child survival, previous studies have exclusively focused on... more

Download (122)

View PDF (115)

Global report on children with developmental disabilities

World Health Organisation (WHO) (2023) C_WHO

Developmental disabilities are common. Yet, children with developmental disabilities have been neglected in health systems planning and policy provisions for health and continue to experience stigmatization, institutionalization, barriers to access health care and inequalities in health and educatio... more

Download (138)

View PDF (144)

Voluntary non-remunerated blood donations to ensure blood safety in the WHO South-East Asia Region to support universal health coverage

World Health Organisation (WHO) (2023) C_WHO

Access to safe blood and blood products is recognized as one of the key requirements for delivery of modern health care in the journey towards health for all. The foundation of safe and sustainable blood supplies depends on the collection of blood from voluntary non-remunerated and low-risk donors. ... more

Download (245)

View PDF (328)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (401)

View PDF (121)

National Guideline For Emergency Nutrition Intervention (May 2022)

Government of Ethiopia (2022) CC

Humanitarian crises exacerbate nutritional risks and often lead to an increase in acute malnutrition. Emergencies include both manmade (conflict) and natural disasters (floods, drought, cyclones, typhoons, earthquakes, volcanic eruptions, etc.). Complex emergencies are combinations of both manmade a... more

Download (149)

View PDF (102)

Global Malaria Programme operational strategy 2024–2030
recommended

World Health Organization WHO (2024) C_WHO

Ahead of World Malaria Day, the WHO Global Malaria Programme published a new operational strategy outlining its priorities and key activities up to 2030 to help change the trajectory of malaria trends, with a view to achieving the global malaria targets. The strategy outlines 4 strategic objectives ... more

Download (27)

View PDF (58)

WHO clinical consortium on healthy ageing 2023

World Health Organisation (WHO) (2024) C_WHO

The 2023 meeting of the WHO Clinical Consortium on Healthy Ageing (CCHA) was the group’s ninth gathering and took place in Geneva 5–7 December 2023. The meeting was structured around seven panels, with a series of technical presentations, plenary discussions and group work, and a final session o... more

Global Malaria Programme operational strategy 2024–2030 recommended

Global Malaria Programme operational strategy 2024–2030
recommended